- Home
- TRNR vs APLM Comparison
TRNR vs APLM Comparison
Compare TRNR & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRNR
- APLM
- Stock Information
- Founded
- TRNR 2017
- APLM 2016
- Country
- TRNR United States
- APLM United States
- Employees
- TRNR N/A
- APLM N/A
- Industry
- TRNR Consumer Electronics/Appliances
- APLM Blank Checks
- Sector
- TRNR Technology
- APLM Finance
- Exchange
- TRNR Nasdaq
- APLM Nasdaq
- Market Cap
- TRNR 6.8M
- APLM 6.9M
- IPO Year
- TRNR 2023
- APLM N/A
- Fundamental
- Price
- TRNR $0.79
- APLM $5.14
- Analyst Decision
- TRNR
- APLM Strong Buy
- Analyst Count
- TRNR 0
- APLM 1
- Target Price
- TRNR N/A
- APLM $200.00
- AVG Volume (30 Days)
- TRNR 1.7M
- APLM 23.1K
- Earning Date
- TRNR 05-19-2025
- APLM 04-03-2025
- Dividend Yield
- TRNR N/A
- APLM N/A
- EPS Growth
- TRNR N/A
- APLM N/A
- EPS
- TRNR N/A
- APLM N/A
- Revenue
- TRNR $5,380,000.00
- APLM $198,000.00
- Revenue This Year
- TRNR $355.02
- APLM $415.15
- Revenue Next Year
- TRNR N/A
- APLM N/A
- P/E Ratio
- TRNR N/A
- APLM N/A
- Revenue Growth
- TRNR 459.25
- APLM N/A
- 52 Week Low
- TRNR $0.62
- APLM $4.71
- 52 Week High
- TRNR $996.00
- APLM $42.00
- Technical
- Relative Strength Index (RSI)
- TRNR 47.02
- APLM 34.26
- Support Level
- TRNR $0.56
- APLM $5.00
- Resistance Level
- TRNR $0.74
- APLM $5.86
- Average True Range (ATR)
- TRNR 0.08
- APLM 0.61
- MACD
- TRNR 0.03
- APLM -0.04
- Stochastic Oscillator
- TRNR 76.69
- APLM 5.57
About TRNR Interactive Strength Inc.
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.